Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology.
about
Induction of steatohepatitis (NASH) with insulin resistance in wildtype B6 mice by a western-type diet containing soybean oil and cholesterol.A casein hydrolysate based formulation attenuates obesity and associated non-alcoholic fatty liver disease and atherosclerosis in LDLr-/-.Leiden mice.Intervention with a caspase-1 inhibitor reduces obesity-associated hyperinsulinemia, non-alcoholic steatohepatitis and hepatic fibrosis in LDLR-/-.Leiden mice.Intravenous Mycobacterium Bovis Bacillus Calmette-Guérin Ameliorates Nonalcoholic Fatty Liver Disease in Obese, Diabetic ob/ob Mice.Replacement of Dietary Saturated Fat by PUFA-Rich Pumpkin Seed Oil Attenuates Non-Alcoholic Fatty Liver Disease and Atherosclerosis Development, with Additional Health Effects of Virgin over Refined OilDiffuse reflectance spectroscopy accurately quantifies various degrees of liver steatosis in murine models of fatty liver disease.The CCR2 Inhibitor Propagermanium Attenuates Diet-Induced Insulin Resistance, Adipose Tissue Inflammation and Non-Alcoholic Steatohepatitis.Probiotic mixture improves fatty liver disease by virtue of its action on lipid profiles, leptin, and inflammatory biomarkers.Reduction of obesity-associated white adipose tissue inflammation by rosiglitazone is associated with reduced non-alcoholic fatty liver disease in LDLr-deficient mice.Overactivation of intestinal Sterol Response Element Binding Protein 2 promotes diet-induced non-alcoholic steatohepatitis.Butyrate restores HFD-induced adaptations in brain function and metabolism in mid-adult obese mice.Surgical removal of inflamed epididymal white adipose tissue attenuates the development of non-alcoholic steatohepatitis in obesity.NAFLD and Atherosclerosis Are Prevented by a Natural Dietary Supplement Containing Curcumin, Silymarin, Guggul, Chlorogenic Acid and Inulin in Mice Fed a High-Fat Diet.Improving Metabolic Health Through Precision Dietetics in Mice.The mitochondrial pyruvate carrier mediates high fat diet-induced increases in hepatic TCA cycle capacity.Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis.Intermittent calorie restriction largely counteracts the adverse health effects of a moderate-fat diet in aging C57BL/6J mice.Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse Model.Metformin improves nonalcoholic fatty liver disease in obese mice via down-regulation of apolipoprotein A5 as part of the AMPK/LXRα signaling pathway.The soluble guanylate cyclase stimulator IW-1973 prevents inflammation and fibrosis in experimental non-alcoholic steatohepatitis.Nonalcoholic Fatty Liver Disease Is Exacerbated in High-Fat Diet-Fed Gnotobiotic Mice by Colonization with the Gut Microbiota from Patients with Nonalcoholic Steatohepatitis.Ferric Citrate Supplementation Reduces Red-Blood-Cell Aggregation and Improves CD163+ Macrophage-Mediated Hemoglobin Metabolism in a Rat Model of High-Fat-Diet-Induced Obesity.Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.CAT-2003: A novel sterol regulatory element-binding protein inhibitor that reduces steatohepatitis, plasma lipids, and atherosclerosis in apolipoprotein E*3-Leiden mice.Pathological characterization and morphometric analysis of hepatic lesions in SHRSP5/Dmcr, an experimental non-alcoholic steatohepatitis model, induced by high-fat and high-cholesterol diet.Key Inflammatory Processes in Human NASH Are Reflected in Ldlr-/-.Leiden Mice: A Translational Gene Profiling Study.Multiple liver insults synergize to accelerate experimental hepatocellular carcinoma.The prebiotic inulin modulates gut microbiota but does not ameliorate atherosclerosis in hypercholesterolemic APOE*3-Leiden.CETP miceSoybean Oil-Derived Poly-Unsaturated Fatty Acids Enhance Liver Damage in NAFLD Induced by Dietary CholesterolThiazolidinedione induces a therapeutic effect on hepatosteatosis by regulating stearoyl-CoA desaturase-1, lipase activity, leptin and resistin
P2860
Q33678636-8585D5CE-8360-40BF-BA4A-889DE03D93CCQ33874197-1044E173-3C33-422A-A2C1-FBD1985DCC55Q34523876-7216B661-603E-40C7-8537-06E3FDDDE27FQ35651595-A0076741-C6C8-46FB-A37D-6A3DF3ADCC44Q35787531-CDD7EBB1-1C24-4CC3-A7E1-432B3D26A7FBQ36076903-E6AF52C1-2D22-4F80-9017-FE967F355C25Q36246407-8C6806ED-EB0C-4745-8C14-C7F9828E5368Q36249192-B165189B-D60F-4C70-9F1C-017A042C78F1Q37193179-73A00A9E-E57C-46AF-BB07-4F311BDC3B34Q38642491-C54C981B-D6A1-48B8-8B23-EB449884468BQ38951126-D5725AD7-AA4F-48AB-AB9D-E3859D36A233Q40015708-F7D325DF-B09D-46BE-A215-B15227D48201Q42072118-0D901670-64B2-41AB-9F75-43CBB1B4A853Q44877212-352D6A3A-36AF-45EF-9BF1-031BDF207918Q46042913-F56A3DEE-C3EA-4E52-9BDB-063A1AFD7454Q46109785-935E7850-90DE-46AB-AFA9-EA30BA6597DDQ46443002-C11A0B25-EACA-4E16-AAB6-8AFCFF222B32Q47128868-300F7CC4-8F6D-4DF9-9B2D-DE82F1BE5604Q47220544-DE4EA9B3-20A8-4B09-ABBA-3BD0C9616BB6Q47243685-2F3082EC-636B-45C3-9B64-B0564C3551CDQ47430306-1248A741-A2E3-4D19-A7F9-F98123906F2CQ47610759-2F7968DA-1B95-42E0-8358-86FA29122CBDQ49394966-30433E56-46AF-4954-B681-F6DDFD111472Q51754950-7C26AF9E-E082-43F9-AAE4-09E8308CBFA1Q53132566-9A159320-9E10-40A7-8E9E-E01131BA81C3Q55071759-21F4FB96-6982-448A-B711-81E7082CC931Q55692234-44C3879A-EBA3-4C82-90D2-C216CB792950Q58590016-875A04DE-E1EB-488F-B1C2-7BEC3A018DC1Q58722819-A30F6DA7-7FA1-4555-82B7-570BB5132E2BQ58802792-BDBAAF51-68BE-467C-BD17-87CFAF3BDA4D
P2860
Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Establishment of a general NAF ...... ison to human liver pathology.
@ast
Establishment of a general NAF ...... ison to human liver pathology.
@en
Establishment of a general NAF ...... ison to human liver pathology.
@nl
type
label
Establishment of a general NAF ...... ison to human liver pathology.
@ast
Establishment of a general NAF ...... ison to human liver pathology.
@en
Establishment of a general NAF ...... ison to human liver pathology.
@nl
prefLabel
Establishment of a general NAF ...... ison to human liver pathology.
@ast
Establishment of a general NAF ...... ison to human liver pathology.
@en
Establishment of a general NAF ...... ison to human liver pathology.
@nl
P2093
P2860
P1433
P1476
Establishment of a general NAF ...... ison to human liver pathology.
@en
P2093
Anita M van den Hoek
Ann Driessen
Aswin L Menke
Ger H Koek
Jan H Lindeman
Reinout Stoop
Robert Kleemann
P2860
P304
P356
10.1371/JOURNAL.PONE.0115922
P407
P577
2014-12-23T00:00:00Z